Korea Arlico PharmLtd Balance Sheet Health
Financial Health criteria checks 3/6
Korea Arlico PharmLtd has a total shareholder equity of ₩83.7B and total debt of ₩45.4B, which brings its debt-to-equity ratio to 54.3%. Its total assets and total liabilities are ₩164.2B and ₩80.6B respectively.
Key information
54.3%
Debt to equity ratio
₩45.40b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩15.04b |
| Equity | ₩83.66b |
| Total liabilities | ₩80.57b |
| Total assets | ₩164.22b |
Recent financial health updates
Korea Arlico PharmLtd (KOSDAQ:260660) Is Carrying A Fair Bit Of Debt
Nov 12
Is Korea Arlico PharmLtd (KOSDAQ:260660) Using Too Much Debt?
Mar 24Is Korea Arlico PharmLtd (KOSDAQ:260660) A Risky Investment?
Dec 16Recent updates
Korea Arlico PharmLtd (KOSDAQ:260660) Is Carrying A Fair Bit Of Debt
Nov 12There's Reason For Concern Over Korea Arlico Pharm Co.,Ltd.'s (KOSDAQ:260660) Price
Aug 04Is Korea Arlico PharmLtd (KOSDAQ:260660) Using Too Much Debt?
Mar 24Should You Be Adding Korea Arlico PharmLtd (KOSDAQ:260660) To Your Watchlist Today?
Mar 02Korea Arlico PharmLtd's (KOSDAQ:260660) Shareholders Are Down 50% On Their Shares
Feb 12
What Is The Ownership Structure Like For Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)?
Jan 25Should You Use Korea Arlico PharmLtd's (KOSDAQ:260660) Statutory Earnings To Analyse It?
Jan 04Is Korea Arlico PharmLtd (KOSDAQ:260660) A Risky Investment?
Dec 16Are Strong Financial Prospects The Force That Is Driving The Momentum In Korea Arlico Pharm Co.,Ltd.'s KOSDAQ:260660) Stock?
Nov 25Financial Position Analysis
Short Term Liabilities: A260660's short term assets (₩76.1B) exceed its short term liabilities (₩65.3B).
Long Term Liabilities: A260660's short term assets (₩76.1B) exceed its long term liabilities (₩15.3B).
Debt to Equity History and Analysis
Debt Level: A260660's net debt to equity ratio (36.3%) is considered satisfactory.
Reducing Debt: A260660's debt to equity ratio has increased from 44.7% to 54.3% over the past 5 years.
Debt Coverage: A260660's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if A260660's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 13:46 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Korea Arlico Pharm Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jongsun Park | Eugene Investment & Securities Co Ltd. |